This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2004.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 834,453 Years Active: 2004
Title: Martin W Kast: Innovator in Tumor Rejection Antigens
Introduction
Martin W Kast is a notable inventor based in Leiden, Netherlands. He has made significant contributions to the field of immunology, particularly in the development of isolated peptides that play a crucial role in tumor rejection.
Latest Patents
Kast holds a patent for "Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules." This innovative work focuses on the complexes of SEQ ID NO: 12 and HLA-A2, which can be utilized to generate cytotoxic T lymphocytes (CTLs). Furthermore, these complexes can be supplemented with interleukin-6 (IL-6) and interleukin-12 (IL-12) to enhance their effectiveness.
Career Highlights
Throughout his career, Martin W Kast has been dedicated to advancing the understanding of immune responses to tumors. His research has paved the way for potential therapeutic applications in cancer treatment.
Collaborations
Kast has collaborated with esteemed colleagues such as Alan Townsend and Judy Bastin, contributing to a rich exchange of ideas and research findings in the field of immunology.
Conclusion
Martin W Kast's innovative work in the realm of tumor rejection antigens exemplifies the impact of scientific research on cancer therapies. His contributions continue to inspire advancements in immunological treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile